It has recently been reported that light/dark transitions lead to changes in choroidal blood flow. Several observations indicate that these changes in choroidal perfusion are triggered at least in part by neural mechanisms. In the present study we hypothesised that the choroidal blood flow response to changes in retinal illumination may be modified by either the muscarinic receptor antagonist atropine or by the b-receptor antagonist propranolol. In 15 healthy subjects the response of choroidal perfusion was studied in a randomised placebo-controlled three way cross-over study using laser Doppler flowmetry and laser interferometric measurement of fundus pulsation amplitude. Before drug administration a transition from light to dark reduced both choroidal haemodynamic parameters by 8%-12%. Neither propranolol nor atropine altered basal choroidal blood flow or choroidal blood flow responses to light/dark transitions. Our data indicate that neither muscarinic nor b-receptors are involved in the choroidal blood flow response to changes in retinal illumination. Further studies are required to elucidate which mechanisms contribute to this blood flow behaviour of the choroid.
Introduction
There is recent evidence that the choroid changes its blood flow during light/dark transitions. Using different techniques it has been shown that choroidal perfusion is lower in the dark than in light (Fuchsj€ a ager-Mayrl, Polska, Malec, & Schmetterer, 2001; Longo, Geiser, & Riva, 2000) . The reason for this behaviour is unknown and the mechanisms underlying the change in blood flow remain to be elucidated. The increase in oxygen consumption during darkness is unlikely to contribute to the decrease in choroidal perfusion. The concomitant decrease in outer retina pO 2 may potentially lead to a decrease in choroidal pO 2 , but the human choroid has been shown to be insensitive to alterations in arterial blood oxygen tension Schmetterer et al., 1996) .
Based on several observations it has been hypothesised that a neural mechanism is underlying the change in choroidal perfusion rate during light/dark transitions (Fuchsj€ a ager-Mayrl et al., 2001; Longo et al., 2000) . Most importantly a unilateral light/dark transition leads to a decrease in choroidal blood flow in both eyes indicating a neural cross-talk among the eyes (Fuchsj€ a ager- Mayrl et al., 2001) . Based on these previous experiments we hypothesised that the choroidal blood flow response during light/dark transitions may be altered by pharmacological modification of the autonomic nervous system in healthy subjects. Accordingly, the response of the choroid was studied during either muscarinic receptor blockade with atropine or b-receptor blockade with propranolol. This was based on the hypothesis that the decrease in choroidal blood flow during light/dark transitions is either due to withdrawal of cholinergic vasodilatory tone or due to activation of adrenergic vasoconstrictor tone. If this hypothesis remains true one would either expect reduced vasoconstriction (during atropine) or increased vasoconstriction (during propranolol). Choroidal blood flow was assessed with two independent methods, namely laser Doppler flowmetry (Geiser, Diermann, & Riva, 1999; Geiser et al., 2000) and laser interferometric measurement of fundus pulsation amplitude (FPA) (Schmetterer, Lexer, Unfried, Sattmann, & Fercher, 1995) .
Materials and methods

Subjects
After approval from the Ethics Committee of Vienna University School of Medicine was obtained, 15 healthy male non-smoking volunteers were studied (age range: 20-34, mean ± SD: 24.5 ± 3.5). The nature of the study was explained and all subjects gave written consent to participate. Each subject passed a screening examination that included medical history and physical examination, 12-lead electrocardiogram, complete blood count, activated partial thromboplastin time, thrombin time, fibrinogen, clinical chemistry (sodium, potassium, creatinine, uric acid, glucose, cholesterol, triglycerides, alanine aminotransferase, aspartate transcarbamylase, c-glutamyltransferase, alkaline phosphatase, total bilirubin, total protein), hepatitis A, B, C and HIVserology, urine analysis, and a urine drug-screen. Subjects were excluded if any abnormality was found as part of the pretreatment screening unless the investigators considered an abnormality to be clinically irrelevant. Furthermore an ophthalmic examination, including slit lamp biomicroscopy and indirect funduscopy was performed. Inclusion criteria were normal ophthalmic findings and ametropia <3 diopters.
Study designs
The study followed a randomised double masked, placebo-controlled three way cross-over design with propranolol (non-selective b-receptor antagonist), atropine (muscarinic-receptor antagonist) or placebo (physiological saline solution) on separate study days. The washout period between study days was at least 4 days. Prior to the study a sample size calculation was performed. The reproducibility of choroidal blood flow changes during light/dark transition using laser Doppler flowmetry was calculated based on the results of our previous study (Fuchsj€ a ager-Mayrl et al., 2001) . These data were used for the sample size calculation selecting an a-level of 0.05 and a b-level of 0.2. A change in choroidal blood flow in the order of 8% was assumed to be relevant. This lead to a sample size of 15 subjects.
The dose of propranolol and atropine was based on previous trials in healthy humans. Propranolol (Inderal â , Zeneca, Macclesfield, UK) was administered as an intravenous bolus infusion at a dose of 80 lg/kg, followed by a continuous infusion of 1 lg/kg/min over 70 min (De Jonge & Garrel, 1997) . Atropine (Atropinsulfat Lannacher, Lannach, Austria) was infused as an intravenous bolus infusion at a dose of 15 lg/kg, followed by a continuous infusion of 0.15 lg/kg/min over 70 min (Sch€ a afers et al., 1997) . These doses of atropine and propranolol were also used for our previous studies in healthy volunteers investigating mechanisms of retinal and choroidal blood flow regulation during isometric exercise (Jandrasits et al., 2001; Polska et al., 2003) . Two syringes filled with physiological saline solution were prepared as placebo, which were identical in appearance with the atropine and the propranolol syringes to maintain double masked conditions.
In order to ensure constant pupil diameters throughout the experiments tropicamide was instilled into the right eye. After full pupil dilatation was achieved baseline measurements of ocular and systemic haemodynamics were performed. Subjects were then kept in room light for 20 min. The room light consisted of neon lamp illumination with a radiance of approximately 115 lW/cm 2 /steradiant. At the end of this 20 min period baseline measurements of choroidal haemodynamic parameters were performed again. Thereafter the room light was turned off for 20 min. During this period of darkness the radiance was below 0.5 lW/cm 2 /steradiant. At the end of this 20 min period in darkness ocular haemodynamic parameters were assessed again. Finally, the light was turned on and subjects were measured again after 10 min. After completion of this pre-treatment part of the experiment a resting period of 30 min was scheduled. Ten minutes before the end of this resting period full pupil dilation was again achieved by topical administration of tropicamide. Another light/ dark transition period was performed during the last 50 min of drug administration, which was identical to the pretreatment period. Intraocular pressure was measured at the begin and the end of each period. Constant pupil diameters throughout the study period were ensured by repeated measurement with the slit lamp.
Methods
Blood pressure and pulse rate. Systolic, diastolic and mean blood pressures (SBP, DBP and MAP) were measured on the upper arm by an automated oscillometric device (HP-CMS patient monitor, Hewlett Packard, Palo Alto, CA, USA). From these data the pulse pressure amplitude was calculated as PPA ¼ SBP-DBP. Pulse rate (PR) was automatically recorded from a finger pulseoxymetric device (HP-CMS patient monitor).
Intraocular pressure. A slit-lamp mounted Goldmann applanation tonometer was used to measure intraocular pressure (IOP). Before each measurement one drop of 0.4% benoxinate hydrochloride combined with 0.25% fluorescein sodium was used for local anaesthesia of the cornea.
Laser Doppler flowmetry. Subfoveal choroidal blood flow was performed by laser Doppler flowmetry (Riva, Cranstoun, Grunwald, & Petrig, 1994) . In this technique, the vascularized tissue is illuminated by coherent laser light. Light scattered by the moving red blood cells (RBCs) undergoes a frequency shift. In contrast, static tissue scatterers do not change the light frequency, but lead to randomisation of light directions impinging on RBCs. Hence, RBCs receive light from numerous random directions. As the frequency shift is dependent not only on the velocity of the moving RBC, but also on the angle between the wave vectors of the incident and the scattered light, scattering of the light in tissue broadens the Doppler shift power spectrum. From this spectrum, the following flow parameters are calculated (Bonner & Nossal, 1990) : mean RBCs velocity in Hz, blood volume and blood flow (FLOW) in arbitrary units.
In the present study, a compact laser Doppler flowmeter, which has been described in detail in a previous paper, was used for the measurements of the choroidal blood flow parameters (Geiser et al., 1999; Geiser et al., 2000) . The laser beam of a single mode laser diode (785 nm, 90 lW at the cornea) is delivered to the eye via a confocal optical system. The beam diameter at the fundus is nominally 12 lm. The light is collected by a bundle of six fibres with a core diameter of 110 lm, which are arranged on a circle with a diameter of 180 lm (indirect detection). All measurements were performed in the fovea by asking the subject to directly fixate at the beam, which appeared as a small red dot.
Fundus pulsation measurement. Pulse synchronous pulsations of the ocular fundus were recorded with a laser interferometric method (Schmetterer et al., 1995) . The method uses a single mode laser beam with a wavelength of 780 nm for illumination of the subjectÕs eye. The power of the laser beam is approximately 80 lW at a beam diameter of 1 mm. The light is reflected at the anterior surface of the cornea and at the fundus. The light from the front side of the cornea serves as a reference wave. Due to the high coherence length of the laser light the interferences produced by the two waves can be observed. This permits calculation of the relative distance changes between cornea and retina during the cardiac cycle. These distance changes are in the order of several micrometers and are caused by the rhythmic filling of ocular vessels during systole and diastole. The distance between cornea and retina decreases during systole, because the blood volume entering the eye via the arteries exceeds the blood volume leaving the eye via the veins, and increases during diastole. The maximum distance change between the cornea and fundus during the cardiac cycle is called FPA, yielding information on the pulsatile component of ocular blood flow (Schmetterer et al., 1998) .
Data analysis
All responses in choroidal haemodynamic parameters during light/dark transitions were expressed as percentage change from baseline values. The effect of atropine and propranolol on choroidal blood flow changes during light/dark transitions were assessed with a repeated measure ANOVA model. The effect of the light/dark transition was calculated as the time effect. The effect of the administered drugs on these choroidal blood flow changes was calculated as the interaction between treatment and time. All statistical analyses were done using the Statistica â software package (Release 4.5, StatSoft Inc., Tulsa, OK, USA). Data are presented as means ± SD. A two-tailed p < 0:05 was considered the level of significance.
Results
Baseline haemodynamic parameters and baseline IOP on the three study days are presented in Table 1 . All outcome variables were comparable between the three study days. No adverse events were observed with either infusion of atropine or propranolol.
As expected a transition from light to dark caused a decrease in choroidal blood flow and FPA at the pretreatment period (Figs. 1 and 2 ). This decrease was between 8% and 12% (p < 0:001) for choroidal blood flow and between 11% and 12% for FPA (p < 0:001). The change in the outcome parameters was, however, comparable on the three study days (choroidal blood flow: p ¼ 0:73; FPA: p ¼ 0:95). All choroidal outcome parameters returned to baseline levels when the room light was switched on again. In contrast to choroidal perfusion parameters neither systolic or diastolic blood pressure, nor pulse rate or IOP were changed by the light dark transitions (Table 2) .
Atropine and propranolol did not alter choroidal blood flow parameters during light conditions (Figs. 1  and 2 ). All choroidal haemodynamic parameters were within 5% of the pre-treatment value independently of Mean arterial pressure (mm Hg) 84 ± 9 83 ± 10 84 ± 9
Pulse pressure amplitude (mm Hg) 58 ± 10 57 ± 12 56 ± 9
Pulse rate (beats/min) 69 ± 8 71 ± 10 67 ± 6 FPA (lm) 4.5 ± 1.5 4.6 ± 1.5 4.5 ± 1. Table 2) . The drugs were, however, administered at systemically effective doses. Accordingly, propranolol reduced MAP versus placebo (p ¼ 0:003), whereas atropine had no effect on MAP. None of the administered drugs altered PPA (Table 2) . Atropine did, however, strongly increase PR (Table 2) , an effect which was highly significant versus placebo (p < 0:001). The reduction in PR in response to propranolol was also significant (p < 0:001). Light/dark transitions did not affect systemic haemodynamic parameters or IOP during either propranolol, atropine, or placebo. In addition, neither atropine nor propranolol affected the response of choroidal blood flow parameters versus placebo. Choroidal blood flow decreased by 9% during the light/dark transition when propranolol was administered (p ¼ 0:49 versus placebo) and by 12% when atropine was administered (p ¼ 0:10 versus placebo). The results for FPA were comparable and this parameters decreased by 12% in response to the light/dark transition during propranolol infusion (p ¼ 0:99 versus placebo) and by 10% during atropine infusion (p ¼ 0:91 versus placebo).
Discussion
In the present study the hypothesis that the choroidal blood flow response to a light/dark transition may be altered by either b-receptor blockade or by muscarinic receptor blockade was tested in healthy subjects. Whereas the data of this trial confirm previous reports from our laboratory (Fuchsj€ a ager-Mayrl et al., 2001 ) and from another group (Longo et al., 2000) that blood flow reversibly decreases in the dark, none of the pharmacological interventions had an effect on this behaviour.
As compared to our previous study an important methodological difference has to be considered. In the present trial the pupil was dilated with tropicamide. Hence, the light/dark transition in the present study induced a more pronounced change in retinal luminance than in our previous study, but the response in choroidal blood flow parameters was comparable. At present we do not know which change in terms of retinal irradiance is required to provoke a change in choroidal blood flow and a dose/response curve is missing. However, we deemed it important to standardise pupil diameters, because of the known effect of atropine on pupil size.
Previous studies clearly indicate that neural mechanisms contribute to the change in choroidal perfusion during transition from light/dark. In healthy subjects unilateral light dark conditions lead to a decrease in choroidal blood flow in both eyes indicating a cross-talk between both eyes. This is well compatible with previous studies in pigeons, where the mechanism underlying changes in choroidal blood flow changes at different retinal illumination levels has been investigated in some detail (Fitzgerald, Gamlin, Zagvazdin, & Reiner, 1996) . In this species changes in choroidal blood flow evoked by changes in retinal illumination are largely mediated via the suprachiasmatic nucleus and the Edinger Westphal nucleus. One of the lines of evidence supporting (Bill, Stjernschantz, & Alm, 1976; Nakanome, Karita, Izumi, & Tamai, 1995; Stjernschantz, Alm, & Bill, 1976) and of the facial nerve via its parasympathetic preganglionic input to the pterygopalatine ganglion (Ruskell, 1971; Nilsson, Linder, & Bill, 1985; Stjernschantz & Bill, 1980) . Investigation of such phenomena in humans is obviously difficult. In the present study we chose to modify the parasympathetic nervous system with the muscarinic receptor blocker atropine. However, neither the choroidal blood flow response to light/dark transitions nor basal choroidal blood flow were altered by this intervention, although the drug was administered at systemically effective doses. The latter observation is in keeping with our previous data, which show that the choroidal pressure/flow relationship during isometric exercise is not altered by atropine infusion (Polska et al., 2003) . In a previous study in rabbits the nicotine receptor antagonist hexamethonium was capable of changing choroidal blood flow in the choroid (Kiel, 1999) . A human study using administration of hexamethonium is, however, ethically not justified considering the recently reported adverse event profile of this drug (McCarthy, 2001) .
The second drug studied in the present trial was the non-selective b-receptor antagonist propranolol modulating the sympathetic nervous system. Previous data on the role of b-receptors in the control of choroidal blood flow are inconsistent. Catecholaminergic binding sites have been observed in the choroid of the cat (Bruninink, Dawis, Niemeyer, & Lichtensteiger, 1986) . A number of studies investigated the effect of topical b-receptor antagonists used for glaucoma therapy on choroidal perfusion parameters in humans (Boles Carenini, Sibour, & Boles Carenini, 1994; Bosem, Lusky, & Weinreb, 1992; Schmetterer et al., 1997; Yoshida et al., 1991) . Whereas such data may be important for the clinical management of glaucoma, they tell little about the pharmacological relevance of b-receptors in the control of choroidal blood flow, because their instillation is accompanied by an increase in ocular perfusion pressure based on their ocular hypotensive effect. Using very high systemic doses of the b-receptor antagonist timolol Kiel and Patel (1998) reported a small decrease in basal choroidal blood flow without any influence on the choroidal pressure/flow relationship. In our own previous study propranolol did neither influence basal choroidal blood flow nor did it change the choroidal pressure/flow relationship during isometric exercise (Polska et al., 2003) .
In conclusion, the data of the present study confirm that light/dark transitions are associated with a decrease in choroidal blood flow. However, this is neither modulated by administration of propranolol nor by administration of atropine. Hence, further studies are required to elucidate which mechanisms are responsible for this behaviour.
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